CN109790211B - 抗kras-g12d t细胞受体 - Google Patents

抗kras-g12d t细胞受体 Download PDF

Info

Publication number
CN109790211B
CN109790211B CN201780059356.4A CN201780059356A CN109790211B CN 109790211 B CN109790211 B CN 109790211B CN 201780059356 A CN201780059356 A CN 201780059356A CN 109790211 B CN109790211 B CN 109790211B
Authority
CN
China
Prior art keywords
seq
leu
ser
val
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780059356.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109790211A (zh
Inventor
埃里克·特兰
保罗·F·罗宾斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CN202410214235.4A priority Critical patent/CN118063591A/zh
Publication of CN109790211A publication Critical patent/CN109790211A/zh
Application granted granted Critical
Publication of CN109790211B publication Critical patent/CN109790211B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
CN201780059356.4A 2016-08-02 2017-07-31 抗kras-g12d t细胞受体 Active CN109790211B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410214235.4A CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
US62/369,883 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410214235.4A Division CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Publications (2)

Publication Number Publication Date
CN109790211A CN109790211A (zh) 2019-05-21
CN109790211B true CN109790211B (zh) 2024-03-26

Family

ID=59564253

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780059356.4A Active CN109790211B (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体
CN202410214235.4A Pending CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410214235.4A Pending CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Country Status (20)

Country Link
US (6) US10611816B2 (https=)
EP (2) EP4159751A1 (https=)
JP (4) JP6993402B2 (https=)
KR (1) KR102527052B1 (https=)
CN (2) CN109790211B (https=)
AU (3) AU2017306038B2 (https=)
CY (1) CY1125601T1 (https=)
DK (1) DK3494133T3 (https=)
ES (1) ES2928051T3 (https=)
HR (1) HRP20221183T1 (https=)
HU (1) HUE060121T2 (https=)
IL (2) IL264425B2 (https=)
LT (1) LT3494133T (https=)
PL (1) PL3494133T3 (https=)
PT (1) PT3494133T (https=)
RS (1) RS63615B1 (https=)
SG (2) SG11201900654QA (https=)
SI (1) SI3494133T1 (https=)
SM (1) SMT202200379T1 (https=)
WO (1) WO2018026691A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3684799A1 (en) 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
KR20210119468A (ko) * 2019-01-25 2021-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 돌연변이체 ras를 표적화하기 위한 조성물 및 방법
WO2020172332A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021092223A1 (en) * 2019-11-05 2021-05-14 Board Of Regents, The University Of Texas System Hla restricted hormad1 t cell receptors and uses thereof
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021135178A1 (zh) * 2019-12-30 2021-07-08 华夏英泰（北京）生物技术有限公司 一种增强型t细胞受体star及其应用
KR20230058013A (ko) * 2020-05-25 2023-05-02 브리스타 이뮤노테크 리미티드 향상된 합성 t 세포 수용체 및 항원 수용체
WO2022015694A1 (en) * 2020-07-13 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii–restricted drb t cell receptors against ras with g12d mutation
TW202540156A (zh) * 2020-10-02 2025-10-16 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
AU2021381384A1 (en) * 2020-11-20 2023-06-22 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4558152A2 (en) * 2022-07-22 2025-05-28 Board of Regents, The University of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
AU2023397979A1 (en) * 2022-12-13 2025-07-03 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025259799A2 (en) * 2024-06-12 2025-12-18 Biontech Us Inc. T cell receptor compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
KR20140100938A (ko) * 2011-11-30 2014-08-18 도쿠리츠교세이호진 고쿠리츠간켄큐센터 유도 악성 줄기세포
SG11201509742QA (en) * 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
JP7185524B2 (ja) 2015-09-15 2022-12-07 アメリカ合衆国 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors;Qiong J Wang,et al;《Cancer Immunol Res.》;20151223;第4卷(第3期);第204-214页 *

Also Published As

Publication number Publication date
WO2018026691A1 (en) 2018-02-08
JP6993402B2 (ja) 2022-02-03
SG10201913959WA (en) 2020-03-30
JP2022050400A (ja) 2022-03-30
CY1125601T1 (el) 2026-02-25
US20220089677A1 (en) 2022-03-24
PL3494133T3 (pl) 2022-11-21
US20190177395A1 (en) 2019-06-13
AU2017306038A1 (en) 2019-02-14
LT3494133T (lt) 2022-12-12
CN109790211A (zh) 2019-05-21
DK3494133T3 (da) 2022-09-19
US20200247869A1 (en) 2020-08-06
HRP20221183T1 (hr) 2022-12-09
US12391742B2 (en) 2025-08-19
IL301894B2 (en) 2025-02-01
IL301894A (en) 2023-06-01
AU2026200276A1 (en) 2026-02-19
JP2024045139A (ja) 2024-04-02
US11897933B2 (en) 2024-02-13
SG11201900654QA (en) 2019-02-27
ES2928051T3 (es) 2022-11-15
AU2023233125A1 (en) 2023-10-12
IL264425B1 (en) 2023-05-01
JP7649370B2 (ja) 2025-03-19
US20210300988A1 (en) 2021-09-30
AU2023233125B2 (en) 2025-10-16
EP3494133A1 (en) 2019-06-12
RS63615B1 (sr) 2022-10-31
PT3494133T (pt) 2022-09-28
US10611816B2 (en) 2020-04-07
US11208456B2 (en) 2021-12-28
SI3494133T1 (sl) 2022-11-30
IL264425B2 (en) 2023-09-01
KR20190064566A (ko) 2019-06-10
EP4159751A1 (en) 2023-04-05
IL301894B1 (en) 2024-10-01
HUE060121T2 (hu) 2023-01-28
JP2019527555A (ja) 2019-10-03
US11840561B2 (en) 2023-12-12
KR102527052B1 (ko) 2023-04-27
JP2025090690A (ja) 2025-06-17
IL264425A (https=) 2019-03-31
JP7413338B2 (ja) 2024-01-15
US20250340611A1 (en) 2025-11-06
US20240209059A1 (en) 2024-06-27
CN118063591A (zh) 2024-05-24
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
EP3494133B1 (en) 2022-07-06
SMT202200379T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
JP7649370B2 (ja) 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
EP3901169B1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
CA3032870C (en) Anti-kras-g12d t cell receptors
HK40008470A (en) Anti-kras-g12d t cell receptors
HK40009637B (en) Anti-kras-g12d t cell receptors
HK40009637A (en) Anti-kras-g12d t cell receptors
HK40008470B (zh) 抗kras-g12d t细胞受体
HK40031140A (en) T cell receptors recognizing mutated p53
HK40031140B (en) T cell receptors recognizing mutated p53
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008470

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Eric Tran

Inventor after: Paul F. Robbins

Inventor after: Steven A. Rosenberg

Inventor before: Eric Tran

Inventor before: Lu Yongcheng

Inventor before: Anna Passeto

Inventor before: Paul F. Robbins

Inventor before: Steven A. Rosenberg

Inventor before: Zheng Zhili

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment